Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784307 | 0.83 | EPHX1 (0.42) | THRBTGFBR1ALDH1A1MGAMGAA | |
| SCHEMBL20589431 | 0.81 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL3738357 | 0.76 | TGFBR1 (0.41) | TGFBR1ALDH1A1 | |
| SCHEMBL97375 | 0.76 | TGFBR1 (0.41) | TGFBR1ALDH1A1 | |
| SCHEMBL14931 | 0.75 | TGFBR1 (0.37) | THRBTGFBR1ALDH1A1 | |
| SCHEMBL5690855 | 0.74 | TSHR (0.43) | ALDH1A1 | |
| SCHEMBL12642676 | 0.74 | TGFBR1 (0.39) | TGFBR1ALDH1A1 | |
| SCHEMBL9759569 | 0.74 | TGFBR1 (0.39) | TGFBR1ALDH1A1 | |
| SCHEMBL16097 | 0.74 | TGFBR1 (0.39) | TGFBR1ALDH1A1 | |
| SCHEMBL9577882 | 0.73 | TGFBR1 (0.44) | THRBTGFBR1ALDH1A1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060776-B2 | Monomers useful in the preparation of separation matrices | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2006-06-13 | — | — | US | disclosed |
| EP-1101101-A4 | METHOD FOR PRODUCING HYDROPHILIC MONOMERS AND USES THEREOF | BIOWHITTAKER MOLUCULAR APPLIC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050113539-A1 | Crosslinked, water insoluble matrix; electrophoresis membranes | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-05-26 | — | — | US | disclosed |
| WO-2003055923-A1 | NOVEL MONOMERS USEFUL IN THE PREPARATION OF SEPARATION MATRICES | AMERSHAM BIOSCIENCES AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-6464850-B1 | CAPILLARY AND MICROCHANNEL ELECTROPHORESIS; HYDROLYTICALLY STABLE,HIGH RESOLUTION; HOMO OR COPOLYMER OF N-(2-HYDROXY ETHYL)ACRYLAMIDE, N-(2-HYDROXYETHYL) METHACRYLAMIDE, N,N-DI(HYDROXYALKYL)ACRYLAMIDE; SUPPRESSES ELECTROENDOOSMOSIS | BIOWHITTAKER MOLECULAR APPLICATIONS, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1101101-A1 | METHOD FOR PRODUCING HYDROPHILIC MONOMERS AND USES THEREOF | Biowhittaker Molucular Applications, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6117293-A | MONOMERS AND CROSSLINKER FOR PREPARING AN ELECTROPHORETIC GEL COMPRISES 75 WEIGHT % OR MORE OF HYDROPHILLIC MONOMER SELECTED FROM N-HYDROXYETHYL(METH)ACRYLAMIDE OR N,N-DIHYDROXYALKYL(METH)ACRYLAMIDE | BIOWHITTAKER MOLECULAR APPLICATIONS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| WO-2000007002-A1 | METHOD FOR PRODUCING HYDROPHILIC MONOMERS AND USES THEREOF | BIOWHITTAKER MOLECULAR APPLICATIONS, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113539-A1 | Crosslinked, water insoluble matrix; electrophoresis membranes | H1-0, H1-4, H1-2 | THRB 4077/4885TGFBR1 633/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.